Tata Institute Mumbai Claims Breakthrough Discovery: Tablet to Prevent Cancer Resurgence

Mumbai: The Tata Institute in Mumbai, a renowned cancer research and treatment facility in India, has announced a groundbreaking discovery that could revolutionize cancer treatment. The institute claims to have developed a tablet capable of preventing the recurrence of cancer and reducing the side effects of treatments like radiation and chemotherapy by 50 percent.

After a decade of dedicated research, the team of researchers and doctors at the Tata Institute has created a tablet that holds the promise of preventing the occurrence of cancer for the second time in patients. Dr. Rajendra Badve, a senior cancer surgeon at Tata Memorial Hospital and part of the research group, explained the innovative approach.

The research involved inserting human cancer cells into rats, forming tumors, and subjecting the rats to radiation therapy, chemotherapy, and surgery. The study revealed that when cancer cells die, they break into tiny particles called Chromatin particles, which can travel through the bloodstream. These particles have the potential to turn healthy cells cancerous when they enter them.

To address this issue, the researchers administered pro-oxidant tablets with resveratrol and copper (R+Cu) to the rats. Dr. Badve explained that R+Cu generates oxygen radicals, which destroy Chromatin Particles. When taken orally, the tablet generates oxygen radicals in the stomach, quickly absorbed into the bloodstream. This process helps prevent the movement of cancer cells (Metastases) and reduces chemotherapy toxicity.

The researchers refer to this breakthrough as the “Magic of R+Cu.” The tablet is expected to significantly decrease the side effects of cancer treatment therapy by approximately 50 percent. Moreover, it demonstrates about 30 percent effectiveness in preventing cancer for the second time and is deemed effective in treating pancreatic, lung, and oral cancer.

While awaiting approval from the Food Safety and Standards Authority of India (FSSAI), the tablet is anticipated to be available in the market by June-July. Dr. Badve stated, “The tablet will be available everywhere for just ₹100, making it an accessible and affordable solution for cancer treatment.”

Human trials are in progress, and it is estimated to take about five years to complete the trials and gain regulatory approval. Despite challenges during the research phase, the success of the tablet marks a significant advancement in cancer treatment and offers hope for improved outcomes in the future.

Source: NDTV